The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

Basit Öğe Kaydı
dc.authoridSadettin Kılıçkap / 0000-0003-1637-7390
dc.authorscopusidSadettin Kılıçkap / 8665552100en_US
dc.authorwosidSadettin Kılıçkap / AAP-3732-2021
dc.contributor.authorYücel, Kadriye Bir
dc.contributor.authorYekedüz, Emre
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorTural, Deniz
dc.contributor.authorErtürk, İsmail
dc.contributor.authorErol, Cihan
dc.contributor.authorErcelep, Özlem
dc.contributor.authorÖztaş Şentürk, Nihan
dc.contributor.authorArslan, Çağatay
dc.contributor.authorUçar, Gökhan
dc.contributor.authorKüçükarda, Ahmet
dc.contributor.authorSever, Özlem Nuray
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorCan, Orçun
dc.contributor.authorYazgan, Satı Çoskun
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorŞendur, Mehmet Ali
dc.contributor.authorÜrün, Yüksel
dc.date.accessioned2022-11-08T13:44:34Z
dc.date.available2022-11-08T13:44:34Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractThis study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kinase inhibitors (TKIs)between January 2007 and June 2020 (i.e., sunitinib, pazopanib) were included in this study. SII was calculated in 621 patients with the following formula:[neutrophil (cellsx109/L) x platelet (cellsx109/L)] / lymphocyte (cellsx109/L).All patients were classified into SII-high and SII-low groups based on the cut-off value of SII at 756, which was the median SII level of our study group. The minimal follow-up duration was 10 months in all cohorts. The median age of patients was 60 (interquartile range (IQR):53–67) years. Three out of four patients were male. The majority of patients (85.7%) had clear cell histology, and sarcomatoid differentiation was observed in 16.9% of all patients. There were 311 and 310 patients in the SII-low and SII-high groups, respectively. In general, baseline characteristics were similar in each group. However, the rate of patients treated with sunitinib (63.3% vs. 49.0%, p < 0.001) and those who underwent nephrectomy (83.6% vs. 64.2%, p < 0.001) was higher in the SII-low group than in the SII-high group. On the other hand, patients with the IMDC poorrisk (31.6% vs. 8.0%, p < 0.001), those with bone (51.8% vs. 32.2%, p < 0.001) or central nervous system (12.9% vs. 5.8%, p = 0.026) metastasis, and those with Eastern Cooperative Oncology Group(ECOG) 2–4 performance score (28.1% vs.17.7%, p = 0.002) were more common in the SII-high group than in the SII-low group. The median overall survival (OS) was longer in the SII-low group than in the SII-high group (34.6 months vs. 14.5 months, p < 0.001). Similarly, the median progression-free survival (PFS) was longer in the SII-low group than in the SII-high group (18.0 months vs. 7.7 months, p < 0.001).In multivariableanalysis, SII was an independent prognostic factor for OS (hazard ratio (HR):1.39, 95% confidence interval (CI):1.05–1.85, p = 0.01) and PFS (HR:1.60, 95% CI:1.24–2.05, p < 0.001).Pre-treatment level of high SII might be considered a predictor of poor prognosisin patients with mRCC treated with TKIs.en_US
dc.identifier.citationYücel, K. B., Yekedüz, E., Karakaya, S., Tural, D., Ertürk, İ., Erol, C., . . . Ürün, Y. (2022). The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors. Scientific Reports, 12(1) doi:10.1038/s41598-022-20056-3en_US
dc.identifier.doi10.1038/s41598-022-20056-3en_US
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-85139172776en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1038/s41598-022-20056-3
dc.identifier.urihttps://hdl.handle.net/20.500.12713/3279
dc.identifier.volume12en_US
dc.identifier.wosWOS:000865282300015en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherNature Researchen_US
dc.relation.ispartofScientific Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleThe relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitorsen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
s41598-022-20056-3.pdf
Boyut:
1.47 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu